A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy

Lung Cancer

Volumn 30, Issue 3, 2000, Pages 193-198

  Kakolyris, S ^a   Souglakos, J ^a   Agelaki, S ^a   Kourousis, Ch ^a   Mavroudis, D ^a   Sarra, E ^a   Malliotakis, P ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Cisplatin; CPT 11; Non small cell lung cancer; Phase I study

Indexed keywords

CISPLATIN; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FEVER; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PACLITAXEL; SALVAGE THERAPY; TAXOIDS;

EID: 0034531970     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(00)00146-X     Document Type: Article

References (10)

1. Irinotecan (CPT-11): Current status and perspectives
2. The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue
3. Enhanced antitumour efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against lung tumour xenografts
4. Effects of CPT-11 in combination with other anticancer agents in culture
5. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer
6. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer
7. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies
8. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high liquid chromatography: Application to plasma pharmacokinetic studies in cancer patients
9. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients